NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting…
$1.33+0.76%
报价 2026-11-06
市值
$143M
EV
–
PE (TTM)
–
预期 PE
–
52 周区间距高点 -77.7%
$1.32$5.97
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| NGENNervGen Pharma Corp. Common stock | $143M | +0.8% | – | 0% | – | – | – | |
| MGNXMacroGenics, Inc. | $148.4M | +5.0% | -21.0% | 50.4% | – | – | – | |
| SIONSionna Therapeutics, Inc. | $148.1M | 0.0% | – | 0% | – | – | – | |
| KRSAKorsana Biosciences, Inc. | $145.4M | +2.0% | – | 61.6% | – | – | – | |
| YARWYarrow Bioscience Inc | $145.1M | +14.7% | – | 97.5% | – | – | – | |
| RNAAvidity Biosciences, Inc. | $142.7M | +0.2% | -61.9% | 100% | – | – | – | |
| MENSJyong Biotech Ltd. Ordinary Shares | $136.8M | +9.1% | – | 0% | – | – | – | |
| CMPXCompass Therapeutics, Inc. | $136.7M | +10.8% | -125.5% | 0% | – | – | – | |
| CUECue Biopharma, Inc. | $136.1M | +4.0% | -84.6% | 99.7% | – | – | – | |
| 同行中位数 | – | – | -73.3% | 56% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 CAD（非美元）暂无季度数据（首次研究运行后填充）。